zonisamide has been researched along with selegiline in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Efimova, J; Ivanovskii, S; Petzer, A; Petzer, JP; Shetnev, A; Shlenev, R; Tarasov, A | 1 |
| Horiuchi, E; Kanazawa, I; Murata, M | 1 |
| Choudhury, ME; Kubo, M; Nagai, M; Nishikawa, N; Nomoto, M; Yabe, H | 1 |
| Choudhury, ME; Kubo, M; Matsuda, S; Moritoyo, T; Nagai, M; Nishikawa, N; Nomoto, M; Yabe, H | 1 |
| Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R | 1 |
2 review(s) available for zonisamide and selegiline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Network Meta-Analysis; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Zonisamide | 2023 |
1 trial(s) available for zonisamide and selegiline
| Article | Year |
|---|---|
Zonisamide has beneficial effects on Parkinson's disease patients.
Topics: Aged; Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Isoxazoles; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Rats; Selegiline; Treatment Outcome; Zonisamide | 2001 |
3 other study(ies) available for zonisamide and selegiline
| Article | Year |
|---|---|
1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B.
Topics: Amino Acid Sequence; Antidepressive Agents; Benzenesulfonamides; Benzoates; Binding Sites; Drug Evaluation, Preclinical; Humans; Isomerism; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxadiazoles; Protein Binding; Protein Conformation; Structure-Activity Relationship; Sulfonamides; Zonisamide | 2019 |
Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anticonvulsants; Biogenic Amines; Brain Chemistry; Callithrix; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Homovanillic Acid; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neostriatum; Neurons; Selegiline; Zonisamide | 2009 |
Zonisamide attenuates MPTP neurotoxicity in marmosets.
Topics: Animals; Antiparkinson Agents; Callithrix; Corpus Striatum; Dopamine; Female; Humans; Isoxazoles; Male; MPTP Poisoning; Neostriatum; Neurons; Neuroprotective Agents; Neurotoxins; Parkinsonian Disorders; Selegiline; Substantia Nigra; Tyrosine 3-Monooxygenase; Zonisamide | 2010 |